We are delighted to note that Summit has announced today that it has met its primary objective in its Phase Ib modified diet clinical trial of SMT C1100 for Duchenne Muscular Dystrophy (DMD), with 50% of patients achieving the desired blood plasma levels. This is very encouraging and highlights the significant potential of the group’s utrophin modulator approach in the treatment of DMD. The positive results enable the group to commence a Phase II open label trial in Q4 2015 and placebo controlle ....
